Siqia Chen, Sisi Xie, Wenzhen He, Duncan Wei, Shunxian Li, Wenjie Chen
Department of Neurology, First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China (mainland)
Med Sci Monit 2017; 23:4401-4407
To investigate the combination of beraprost sodium (BPS) and aspirin in the treatment of acute ischemic stroke (AIS).
MATERIAL AND METHODS: 308 patients with acute cerebral infarction were randomly divided into two groups: experimental group (n=154), treated with BPS (40 μg, tid) and aspirin (100 mg, qd); control group (n=154), treated with 100 mg of aspirin, qd). The antiplatelet therapy remained unchangeable until six months after hospital discharge.
RESULTS: Initially, no significant differences were found between the two groups. After six months, the relapse-free survival rate was similar between the treatment group (98.1%) and the control group (97.4%). One patient died from AIS in the control group. However, glomerular filtration rate was significantly higher; neurological function and functional ability of patients were better in patients treated with BPS plus aspirin (experimental group) than that in aspirin alone group. No significant difference was found in the function of the coagulation system, suggesting that BPS plus aspirin treatment did not increase the risk of bleeding. Serious adverse events did not occur in both groups. Facial flushing (one case) and mild gastrointestinal reaction (one case) were found in the treatment group without influencing treatment.
CONCLUSIONS: In our trial involving patients with acute cerebral infarction, BPS plus aspirin was not found to be superior to aspirin in reducing the recurrence of cerebral infarction or death. However, BPS plus aspirin treatment could improve renal function and neurological function without increasing the risk of bleeding.
Keywords: Nervous System Diseases, Nontherapeutic Human Experimentation, Stroke